RU2008126228A - 2-аминобензамидное производное - Google Patents

2-аминобензамидное производное Download PDF

Info

Publication number
RU2008126228A
RU2008126228A RU2008126228/04A RU2008126228A RU2008126228A RU 2008126228 A RU2008126228 A RU 2008126228A RU 2008126228/04 A RU2008126228/04 A RU 2008126228/04A RU 2008126228 A RU2008126228 A RU 2008126228A RU 2008126228 A RU2008126228 A RU 2008126228A
Authority
RU
Russia
Prior art keywords
lower alkyl
ring
group
halogen
oxo
Prior art date
Application number
RU2008126228/04A
Other languages
English (en)
Inventor
Такахиро КУРАМОТИ (JP)
Такахиро КУРАМОТИ
Риодзи ХИРАБАЯСИ (JP)
Риодзи ХИРАБАЯСИ
Йохеи КОГАНЕМАРУ (JP)
Йохеи Коганемару
Риосуке МУНАКАТА (JP)
Риосуке МУНАКАТА
Коити ЙОНЕЗАВА (JP)
Коити ЙОНЕЗАВА
Тецуо КИСО (JP)
Тецуо Кисо
Original Assignee
Астеллас Фарма Инк. (Jp)
Астеллас Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Инк. (Jp), Астеллас Фарма Инк. filed Critical Астеллас Фарма Инк. (Jp)
Publication of RU2008126228A publication Critical patent/RU2008126228A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
    • C07C37/18—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by condensation involving halogen atoms of halogenated compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

1. Ингибитор активации VR1, который включает 2-аминобензамидное производное общей формулы (I) или его соль в качестве активного ингредиента ! ! где - бензольное кольцо или пиридиновое кольцо, ! R3 - одинаковые или отличные друг от друга и каждый представляет собой H, галоген, галоген-низший алкил, циано, нитро, низший алкил, -NR4R5, -низший алкилен-NR4R5, -низший алкилен-NR6-CO2-низший алкил, -O-низший алкил, -O-галоген-низший алкил, фенил или тиенил, ! m - 1, 2 или 3, ! R4 и R5 - одинаковые или отличные друг от друга и каждый представляет собой H или низший алкил, где R4 и R5 могут быть объединены со смежным атомом азота с образованием моноциклического азотсодержащего насыщенного гетерокольца, которое может быть замещено низшим алкилом или группой низший алкилен-OH, ! R6 - H или низший алкил, !- моноциклическое гетерокольцо, циклоалкен или бензольное кольцо, ! где кольцо, представленное как А, может быть замещено 1-4 группами, выбранными из групп -OH, -низший алкилен-OH, -низший алкилен-NR4R5, -низший алкилен-CO-NR4R5, галоген, галоген-низший алкил, низший алкил и оксо, ! R1 - низший алкил, -L-циклоалкил, L-циклоалкенил, -L-моноциклическое кислородсодержащее насыщенное гетерокольцо, -L-моноциклическое азотсодержащее насыщенное гетерокольцо, -L- азотсодержащее насыщенное гетерокольцо, содержащее мостиковую связь, -L-фенил или -L-пиридил, при условии, что тип кольца A, когда R1 представляет собой низший алкил, подразумевает кольцо, которое образует индолин, тетрагидрохинолин или 3,4-дигидро-2H-1,4-бензоксазин вместе с бензольным кольцом, с которым оно конденсировано, ! где низший алкил в группе R1 может быть замещен 1-3 группами, выбранными из групп, представленных в описанной ниже гр�

Claims (15)

1. Ингибитор активации VR1, который включает 2-аминобензамидное производное общей формулы (I) или его соль в качестве активного ингредиента
Figure 00000001
где
Figure 00000002
- бензольное кольцо или пиридиновое кольцо,
R3 - одинаковые или отличные друг от друга и каждый представляет собой H, галоген, галоген-низший алкил, циано, нитро, низший алкил, -NR4R5, -низший алкилен-NR4R5, -низший алкилен-NR6-CO2-низший алкил, -O-низший алкил, -O-галоген-низший алкил, фенил или тиенил,
m - 1, 2 или 3,
R4 и R5 - одинаковые или отличные друг от друга и каждый представляет собой H или низший алкил, где R4 и R5 могут быть объединены со смежным атомом азота с образованием моноциклического азотсодержащего насыщенного гетерокольца, которое может быть замещено низшим алкилом или группой низший алкилен-OH,
R6 - H или низший алкил,
Figure 00000003
- моноциклическое гетерокольцо, циклоалкен или бензольное кольцо,
где кольцо, представленное как А, может быть замещено 1-4 группами, выбранными из групп -OH, -низший алкилен-OH, -низший алкилен-NR4R5, -низший алкилен-CO-NR4R5, галоген, галоген-низший алкил, низший алкил и оксо,
R1 - низший алкил, -L-циклоалкил, L-циклоалкенил, -L-моноциклическое кислородсодержащее насыщенное гетерокольцо, -L-моноциклическое азотсодержащее насыщенное гетерокольцо, -L- азотсодержащее насыщенное гетерокольцо, содержащее мостиковую связь, -L-фенил или -L-пиридил, при условии, что тип кольца A, когда R1 представляет собой низший алкил, подразумевает кольцо, которое образует индолин, тетрагидрохинолин или 3,4-дигидро-2H-1,4-бензоксазин вместе с бензольным кольцом, с которым оно конденсировано,
где низший алкил в группе R1 может быть замещен 1-3 группами, выбранными из групп, представленных в описанной ниже группе G, и циклоалкил, циклоалкенил, моноциклическое кислородсодержащее насыщенное гетерокольцо, моноциклическое азотсодержащее насыщенное гетерокольцо, фенил и пиридил в группе R1 могут быть замещены 1-5 группами, выбранными из групп, представленных ниже в определении группы G, и низшего алкила, который может быть замещен группой, представленной в определении группы G,
группа G - -O-низший алкил, -OH, оксо, -S(O)p-низший алкил, -NR4R5, -NR6-CO2-низший алкил, -NR6-SO2-низший алкил, -N+(низший алкил)3, -CO2-низший алкил, -CO-NR4R5, галоген, фенил, циклоалкил, -O-низший алкилен-фенил, -NR6-циклоалкил и моноциклическое кислородсодержащее насыщенное гетерокольцо,
p - 0, 1 или 2,
L - связь или низший алкилен,
R2 - одинаковые или отличные друг от друга и каждый представляет собой H, низший алкил, галоген, галоген-низший алкил или -OH, и
n - 1 или 2.
2. Ингибитор активации VR1, который включает 2-аминобензамидное производное или его соль в качестве активного ингредиента, по п.1, где A представляет собой моноциклическое азотсодержащее гетерокольцо, где указанная кольцевая группа содержит оксогруппу или гидроксильную группу в качестве группы заместителя и может быть дополнительно замещена 1 или 2 группами, выбранными из групп -низший алкилен-OH, -низший алкилен-NR4R5, -низший алкилен-CO-NR4R5, галоген, галоген-низший алкил и низший алкил.
3. 2-Аминобензамидное производное общей формулы (I') или его соль
Figure 00000004
где X и W - один представляет собой N, а другой представляет собой CH или оба представляют собой CH,
R3a и R3b - одинаковые или отличные друг от друга и каждый представляет собой H, галоген, галоген-низший алкил, циано, нитро, низший алкил, -NR4R5, -низший алкилен-NR4R5, -низший алкилен-NR6-CO2-низший алкил, -O-низший алкил, -O-галоген-низший алкил, фенил или тиенил,
R4 и R5 - одинаковые или отличные друг от друга и каждый представляет собой H или низший алкил, где R4 и R5 могут быть объединены со смежным атомом азота с образованием моноциклического азотсодержащего насыщенного гетерокольца, которое может быть замещено низшим алкилом или группой низший алкилен-OH,
R6 - H или низший алкил,
Figure 00000003
- моноциклическое гетерокольцо, циклоалкен или бензольное кольцо,
где кольцо, представленное как А, может быть замещено 1-4 группами, выбранными из групп -OH, -низший алкилен-OH, -низший алкилен-NR4R5, -низший алкилен-CO-NR4R5, галоген, галоген-низший алкил, низший алкил и оксо,
R1 - низший алкил, циклоалкил, циклоалкенил, моноциклическое кислородсодержащее насыщенное гетерокольцо, моноциклическое азотсодержащее насыщенное гетерокольцо, фенил или пиридил, при условии, что тип кольца A, когда R1 представляет собой низший алкил, подразумевает кольцо, которое образует индолин, тетрагидрохинолин или 3,4-дигидро-2H-1,4-бензоксазин вместе с бензольным кольцом, с которым оно конденсировано,
где низший алкил в группе R1 может быть замещен 1-3 группами, выбранными из групп, представленных ниже в определении группы G, и циклоалкил, циклоалкенил, моноциклическое кислородсодержащее насыщенное гетерокольцо, моноциклическое азотсодержащее насыщенное гетерокольцо, фенил и пиридил в группе R1 могут быть замещены 1-5 группами, выбранными из групп, представленных ниже в определении группы G, и низшего алкила, который может быть замещен группой, представленной в определении группы G,
группа G - -O-низший алкил, -OH, оксо, -S(O)p-низший алкил, -NR4R5, -NR6-CO2-низший алкил, -NR6-SO2-низший алкил, -N+(низший алкил)3, -CO2-низший алкил, -CO-NR4R5, галоген, фенил, циклоалкил, -O-низший алкилен-фенил, -NR6-циклоалкил и моноциклическое кислородсодержащее насыщенное гетерокольцо,
p - 0, 1 или 2,
R2 - одинаковые или отличные друг от друга и каждый представляет собой H, низший алкил, галоген, галоген-низший алкил или -OH, и
n - 1 или 2.
4. Производное и его соль по п.3, где X представляет собой N или CH, W представляет собой CH и A представляет собой моноциклическое азотсодержащее гетерокольцо, где указанная кольцевая группа содержит оксогруппу или гидроксильную группу в качестве группы заместителя и может быть дополнительно замещена 1 или 2 группами, выбранными из группы, содержащей -низший алкилен-OH, -низший алкилен-NR4R5, -низший алкилен-CO-NR4R5, галоген, галоген-низший алкил и низший алкил.
5. Производное и его соль по п.4, где тип кольца A представляет собой кольцо, которое образует индолин, тетрагидрохинолин или 3,4-дигидро-2H-1,4-бензоксазин вместе с бензольным кольцом, с которым оно конденсировано.
6. Производное и его соль по п.5, где R1 представляет собой кольцевую группу, выбранную из циклоалкила, циклоалкенила, моноциклического кислородсодержащего насыщенного гетерокольца и моноциклического азотсодержащего насыщенного гетерокольца, которое может быть замещено 1-5 группами, выбранными из групп, представленных в определении группы G, и низшего алкила, который может быть замещен группой, представленной в определении группы G.
7. Производное и его соль по п.6, где R1 представляет собой кольцевую группу, выбранную из циклоалкила, диоксоланила и пиперидила, которая может быть замещена низшим алкилом, -NR4R5 или циклоалкилом.
8. Производное и его соль по п.4, где R1 представляет собой кольцевую группу, выбранную из циклоалкила, циклоалкенила, моноциклического кислородсодержащего насыщенного гетерокольца, моноциклического азотсодержащего насыщенного гетерокольца, фенила и пиридила, которая может быть замещена 1-5 группами, выбранными из групп, представленных в определении группы G, и низшего алкила, который может быть замещен группой, представленной в определении группы G.
9. Производное и его соль по п.8, где R1 представляет собой кольцевую группу, выбранную из циклоалкила, диоксоланила и пиперидила, которая может быть замещена низшим алкилом, -NR4R5 или циклоалкилом.
10. Производное по п.3 или его фармацевтически приемлемая соль, выбранные из группы, включающей 4-хлор-N-(1-метил-2-оксо-1,2,3,4-тетрагидрохинолин-7-ил)-2-{[(1S,2S)-2-пирролидин-1-илциклогексил]амино}бензамид, 2-(циклогексиламино)-N-(2-метил-3-оксо-3,4-дигидро-2H-1,4-бензоксазин-6-ил)-4-(трифторметил)бензамид, 4-хлор-N-[(2R)-2-метил-3-оксо-3,4-дигидро-2H-1,4-бензоксазин-6-ил]-2-{[(1R,2S)-2-пирролидин-1-илциклогексил]амино}бензамид, N-[2-оксо-4-(трифторметил)-2,3-дигидро-1H-индол-6-ил]-2-{[(1S,2S)-2-пирролидин-1-илциклогексил]амино}-4-(трифторметил)бензамид, N-(1-метил-2-оксо-1,2,3,4-тетрагидрохинолин-7-ил)-2-(пиридин-4-иламино)-4-(трифторметил)бензамид, N-(3,3-диметил-2-оксо-2,3-дигидро-1H-индол-6-ил)-2-{[(1S,2S)-2-пирролидин-1-илциклогексил]амино}-4-(трифторметил)бензамид, N-(3,3-диметил-2-оксо-2,3-дигидро-1H-индол-6-ил)-2-{[(1R,2R)-2-пирролидин-1-илциклогексил]амино}-4-(трифторметил)бензамид, 2-{[(1R,2R)-2-(диметиламино)циклогексил]амино}-N-[(2R)-2-метил-3-оксо-3,4-дигидро-2H-1,4-бензоксазин-6-ил]-4-(трифторметил)бензамид, 2-{[(1S,2S)-2-(диметиламино)циклогексил]амино}-N-(3,3-диметил-2-оксо-2,3-дигидро-1H-индол-6-ил)-4-(трифторметил)бензамид, N-(3,3-диметил-2-оксо-2,3-дигидро-1H-индол-6-ил)-2-[(1-изобутилпиперидин-4-ил)амино]-4-(трифторметил)бензамид, N-(3,3-диметил-2-оксо-2,3-дигидро-1H-индол-6-ил)-2-{[(3S)-1-пентилпирролидин-3-ил]амино}-4-(трифторметил)бензамид, N-(2-оксо-1,2-дигидрохинолин-7-ил)-2-{[(1R,2R)-2-пирролидин-1-илциклогексил]амино}-4-(трифторметил)бензамид, N-(3,3-диметил-2-оксо-2,3-дигидро-1H-индол-6-ил)-2-{[(3S)-1-пентилпирролидин-3-ил]амино}-4-(трифторметил)бензамид, 2-[(1-бутилпиперидин-4-ил)амино]-N-(3,3-диметил-2-оксо-2,3-дигидро-1-H-индол-6-ил)-4-(трифторметил)бензамид, N-(3,3-диметил-2-оксо-2,3-дигидро-1H-индол-6-ил)-2-{[(1S,2R)-2-пирролидин-1-илциклогексил]амино}-4-(трифторметил)бензамид, 2-{[(1S,2R)-2-пирролидин-1-илциклогексил]амино}-N-хинолин-7-ил-4-(трифторметил)бензамид, 2-{[(1S,2S)-2-пирролидин-1-илциклогексил]амино}-N-хинолин-7-ил-4-(трифторметил)бензамид и N-[2-оксо-4-(трифторметил)-2,3-дигидро-1H-индол-6-ил]-2-{[(1S,2R)-2-пирролидин-1-илциклогексил]амино}-6-(трифторметил)никотинамид.
11. Фармацевтическая композиция, которая включает производное по п.3 или его фармацевтически приемлемую соль и фармацевтически приемлемый носитель.
12. Фармацевтическая композиция по п.11, которая представляет собой ингибитор активации VR1.
13. Фармацевтическая композиция по п.11, которая представляет собой средство для лечения или предупреждения ноцицептивной боли, невропатической боли, раковой боли, головной боли, расстройства функции мочевого пузыря.
14. Применение производного по п.3 или его фармацевтически приемлемой соли для получения средства для лечения или предупреждения ноцицептивной боли, невропатической боли, раковой боли, головной боли, расстройства функции мочевого пузыря.
15. Способ лечения или предупреждения ноцицептивной боли, невропатической боли, раковой боли, головной боли, расстройства функции мочевого пузыря, который включает введение терапевтически эффективного количества производного по п.2 или его фармацевтически приемлемой соли пациенту.
RU2008126228/04A 2005-11-30 2006-11-29 2-аминобензамидное производное RU2008126228A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005345502 2005-11-30
JP2005-345502 2005-11-30

Publications (1)

Publication Number Publication Date
RU2008126228A true RU2008126228A (ru) 2010-01-10

Family

ID=38092260

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008126228/04A RU2008126228A (ru) 2005-11-30 2006-11-29 2-аминобензамидное производное

Country Status (11)

Country Link
US (1) US8106190B2 (ru)
EP (1) EP1955697B1 (ru)
JP (1) JP5169220B2 (ru)
KR (1) KR20080071562A (ru)
CN (1) CN101312720A (ru)
AU (1) AU2006319916A1 (ru)
BR (1) BRPI0619208A2 (ru)
CA (1) CA2629964A1 (ru)
ES (1) ES2384643T3 (ru)
RU (1) RU2008126228A (ru)
WO (1) WO2007063925A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CA2680312A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
EP2183241B1 (en) 2007-05-03 2012-12-19 Pfizer Limited 2-pyridine carboxamide derivatives as sodium channel modulators
US8129390B2 (en) * 2007-12-12 2012-03-06 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using the same
KR101619341B1 (ko) 2008-01-28 2016-05-11 (주)아모레퍼시픽 바닐로이드 수용체 길항체로서의 신규 화합물, 이의 이성질체 또는 약제학적으로 허용가능한 염, 및 이를 함유하는 약학 조성물
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2307394B1 (en) 2008-07-02 2012-09-26 Amorepacific Corporation Sulphonamides as vanilloid receptor antagonist
ES2444777T3 (es) 2009-06-12 2014-02-26 Bristol-Myers Squibb Company Compuestos de nicotinamida útiles como moduladores de quinasas
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
WO2014040969A1 (en) * 2012-09-13 2014-03-20 F. Hoffmann-La Roche Ag 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
TWI771319B (zh) 2016-09-09 2022-07-21 美商英塞特公司 吡唑并吡啶化合物及其用途
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
WO2018085348A1 (en) * 2016-11-03 2018-05-11 Actavalon, Inc. Substituted quinolines and methods for treating cancer
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
PT3755703T (pt) 2018-02-20 2022-08-16 Incyte Corp Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida e compostos relacionados como inibidores de hpk1 para o tratamento do cancro
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP3856348B1 (en) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
TW202114680A (zh) 2019-08-06 2021-04-16 美商英塞特公司 Ｈｐｋ１抑制劑之固體形式

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60115480A (ja) 1983-11-29 1985-06-21 Usac Electronics Ind Co Ltd 郵便番号印字機能を持つ印字装置
US4801604A (en) 1985-10-25 1989-01-31 The Upjohn Company Cis-N-(2-aminocycloaliphatic)benzamide anti-convulsants
JPH1113989A (ja) 1997-06-24 1999-01-22 Fuji Oozx Inc 潤滑油の供給容器
JPH11171848A (ja) 1997-09-26 1999-06-29 Fujirebio Inc 芳香族アミド誘導体
JP3013989B2 (ja) 1998-03-26 2000-02-28 日本たばこ産業株式会社 アミド誘導体及びノシセプチンアンタゴニスト
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (ru) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Translated By PlajАМИДЫ АНТРАНИЛОВОЙ КИСЛОТЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕЧЕБНЫХ СРЕДСТВ
JP3707765B2 (ja) 1999-09-09 2005-10-19 株式会社村田製作所 電界効果型半導体装置
DE10023484A1 (de) 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
JP4131734B2 (ja) 2000-11-17 2008-08-13 三菱重工業株式会社 洗濯排水の処理装置
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
PL364478A1 (en) * 2001-05-08 2004-12-13 Schering Aktiengesellschaft Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
US20050072681A1 (en) 2001-12-03 2005-04-07 Microfabrica Inc. Multi-step release method for electrochemically fabricated structures
JP4031720B2 (ja) 2002-03-22 2008-01-09 富士フイルム株式会社 画像読取装置における鮮鋭度補正方法および装置
JP2004007457A (ja) 2002-04-25 2004-01-08 Sony Corp 通信システム、通信制御装置及び通信制御方法、通信装置及び通信方法、並びにコンピュータ・プログラム
JP2004005279A (ja) 2002-05-31 2004-01-08 Ricoh Co Ltd タッチパネル付きディスプレイ装置、電子黒板装置、タッチパネル付きディスプレイ装置の制御方法およびその方法をコンピュータに実行させるためのプログラム
US20040039019A1 (en) * 2002-06-19 2004-02-26 Schering Ag Selected anthranilaminde pyridinamides and their use as pharmaceutical agents
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
DE10231519A1 (de) 2002-07-12 2004-01-22 Fischer Automotive Systems Gmbh Halter für einen Getränkebehälter
JP2004051755A (ja) 2002-07-18 2004-02-19 Ricoh Co Ltd 弾性導電樹脂及び弾性導電接合構造
DE20213065U1 (de) * 2002-08-21 2003-01-23 Mc Menemy, James, 10825 Berlin Überlappende, verschliessbare Schlitzöffnung speziell für Stillbekleidung
JP4040405B2 (ja) 2002-09-20 2008-01-30 富士通株式会社 不揮発性半導体記憶セルの制御方法、および不揮発性半導体記憶装置
KR100449073B1 (ko) 2002-10-15 2004-09-18 한국전자통신연구원 리튬 이차 전지용 양극 활물질 및 그 제조 방법
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
TWI306855B (en) 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
TW200505450A (en) 2003-02-03 2005-02-16 Janssen Pharmaceutica Nv Quinoline-derived amide modulators of vanilloid VR1 receptor
JP4909068B2 (ja) 2003-02-14 2012-04-04 グラクソ グループ リミテッド カルボキサミド誘導体
WO2004108133A2 (en) * 2003-06-05 2004-12-16 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
AU2004247559B2 (en) 2003-06-12 2009-08-27 Astellas Pharma Inc. Benzamide derivative or salt thereof
WO2005072681A2 (en) 2004-01-23 2005-08-11 Amgen Inc. Vanilloid receptor ligands and their use in treatments of inflammatory and neurotic pain.
DE102004039876A1 (de) 2004-06-23 2006-01-26 Lanxess Deutschland Gmbh Herstellung von fluorierten 1,3-Benzodioxanen
JP2008515884A (ja) * 2004-10-08 2008-05-15 アストラゼネカ・アクチエボラーグ 新規なヒドロキシメチルベンゾチアゾールアミド
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors

Also Published As

Publication number Publication date
ES2384643T3 (es) 2012-07-10
EP1955697A1 (en) 2008-08-13
EP1955697A4 (en) 2011-01-26
WO2007063925A1 (ja) 2007-06-07
AU2006319916A1 (en) 2007-06-07
CA2629964A1 (en) 2007-06-07
BRPI0619208A2 (pt) 2011-09-20
EP1955697B1 (en) 2012-05-02
JP5169220B2 (ja) 2013-03-27
US8106190B2 (en) 2012-01-31
US20090233900A1 (en) 2009-09-17
CN101312720A (zh) 2008-11-26
JPWO2007063925A1 (ja) 2009-05-07
KR20080071562A (ko) 2008-08-04

Similar Documents

Publication Publication Date Title
RU2008126228A (ru) 2-аминобензамидное производное
RU2003120512A (ru) Активаторы изоиндолин-1-он-глюкокиназы
RU2403247C2 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
RU2401658C2 (ru) Гетероциклические ингибиторы аспартилпротеазы
RU2008142834A (ru) Модуляция церамидкиназы
RU2006101053A (ru) Производные бензамида или соль указанного производного
RU2424240C2 (ru) Антибактериальные производные пиперидина
RU2328486C2 (ru) Производные 2-пиридона в качестве ингибиторов нейтрофильной эластазы
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
RU2445312C2 (ru) ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
IL264982B (en) Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
JP2007532651A5 (ru)
RU2003110577A (ru) Гетероциклические соединения, связывающиеся с хемокиновыми рецепторами
PE20020566A1 (es) DERIVADOS DE FENILACETAMIDO-PIRAZOLES COMO INHIBIDORES DE LA cdk/CICLINA QUINASA
RU2007105595A (ru) Конденсированное производное бензамида и ингибитор активности подтипа 1 рецептора ваниллоида (vri)
RU2017145650A (ru) Ингибиторы тирозинкиназы брутона
RU2003132687A (ru) Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv
RU99105567A (ru) Производные пропионовой кислоты и их использование
AR044981A1 (es) Combinacion de un inhibidor alosterico de metaloproteinasa de matriz 13 (mmp-13) y un ligando de un receptor alfa-2- delta
JP2015502335A5 (ru)
JP2004506632A5 (ru)
AR029887A1 (es) Compuestos para el tratamiento de la isquemia, su uso en la fabricacion de medicamentos y composiciones que los contienen
CA2376305A1 (en) Sulfonamide and sulfamide substituted imidazoquinolines
AR044719A1 (es) Derivados de fenilo y piridinilo, su uso, un proceso para prepararlos, y medicamentos que los contienen
PE20061319A1 (es) Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20100511